# Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC

> **NCT00001450** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 58 (—)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms

## Interventions

- **DRUG:** paclitaxel
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00001450
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-09
- **Primary completion:** —
- **Final completion:** 2000-06
- **Target enrollment:** 58 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001450, "Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00001450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*